ACM
OTLK icon

Aquatic Capital Management’s Outlook Therapeutics OTLK Stock Holding History

Aquatic Capital Management’s Portfolio OTLK Stock Details OTLK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-5
Closed – – 1469
2022
Q1 		$0 Sell
5
-450
-99% -$14.1K ﹤0.01% 1399
2021
Q4 		$12K Buy
+455
New +$16.2K 0.02% 750

Other funds holding OTLK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LA
LVW Advisors Pittsford, New York $1.16B AUM 26.37% 1-Year Est. Return
VF
Vista Finance Clayton, Missouri $179M AUM 18.59% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Aquatic Capital Management's OTLK Position: Q2 2022 in Review

Aquatic Capital Management sold out of Outlook Therapeutics (OTLK) in Q2 2022, closing a stake of 5 shares.

Aquatic Capital Management first reported a position in OTLK in Q4 2021 and held it in 2 quarters. The position peaked at $12K in Q4 2021. 75 funds tracked by Wall St. Rank hold OTLK as of Q2 2022.

  • Aquatic Capital Management reported no remaining Outlook Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Aquatic Capital Management sold 5 Outlook Therapeutics shares in Q2 2022.
  • Aquatic Capital Management first reported a position in Outlook Therapeutics in Q4 2021 and held it in 2 quarters.
  • Aquatic Capital Management's Outlook Therapeutics position peaked at $12K in Q4 2021.
  • 75 funds tracked by Wall St. Rank held Outlook Therapeutics as of Q2 2022.

Based on Aquatic Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.